Antibacterial agents agent in preclinical development

  16 January 2020

This is the World Health Organization’s first comprehensive overview of the preclinical antibacterial pipeline to date based on publicly available data on each included project. This report and the respective WHO database capture 252 antibacterial agents in development targeting the pathogens on the WHO priority pathogens list, Mycobacterium tuberculosis and Clostridioides difficile. The preclinical pipeline is dynamic and scientifically diverse, with agents being developed in many parts of the world to prevent and treat drug-resistant bacterial infections.


Further reading: WHO
Author(s): WHO
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University

Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!